---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-032698"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:36:52.675395+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave regains full rights to WVE-006; plans FDA accelerated approval engagement mid-2026

## Summary
- Regained full rights to WVE-006 (RNA editing for AATD) from GSK; no upfront payment mentioned.
- Plans to engage FDA on accelerated approval pathway; regulatory feedback expected mid-2026.
- 400 mg multidose cohort data from RestorAATion-2 on track for Q1 2026; 600 mg data expected in 2026.
- GSK collaboration continues; fourth program selected in Jan 2026; potential milestones up to $2.8B.
- Cash runway expected into Q3 2028; milestone payments from GSK not included in runway.

## SEC filing metadata
- accession: 0001193125-26-032698
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312526032698/0001193125-26-032698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312526032698/d78838d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-032698
- JSON: https://secwatch.observer/filing/0001193125-26-032698.json
- Plain text: https://secwatch.observer/filing/0001193125-26-032698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.